The brand-drug lobby asked U.S. Trade Representative Robert Lighthizer on Friday (Feb. 8) to denounce drug-pricing intellectual property practices used in Canada, Malaysia, South Korea, Japan and 11 other countries, and the stakes are higher now that the Trump administration plans to base some drug reimbursement in the United States on prices in foreign countries, including Canada and Japan. In its comments to USTR on this year’s congressionally mandated Special 301 report , PhRMA denounced changes that Canada made to...